miR‐96‐5p regulates cervical cancer cell resistance to cisplatin by inhibiting lncRNA TRIM52‐AS1 and promoting IGF2BP2

Abstract

Abstract MicroRNA (miRNA) and long noncoding RNA (lncRNA) are both regulators of cancer progression. This study sought to discuss the functional mechanism of miR‐96‐5p/lncRNA TRIM52 antisense RNA 1 (head‐to‐head; TRIM52‐AS1) in cervical cancer (CC) cell resistance to cisplatin (DDP). DDP‐resistant CC cell line was established using increasing concentrations of DDP, followed by transfection with miR‐96‐5p inhibitor, or si‐TRIM52‐AS1, or insulin‐like growth factor 2 mRNA binding protein 2 (IGF2BP2) overexpression vector. Expression levels of miR‐96‐5p, TRIM52‐AS1, and IGF2BP2 were determined. Changes in IC50 value to DDP, cell proliferation, and apoptosis rate were evaluated by cell‐counting kit‐8 assay, colony formation, and flow cytometry. The bindings of miR‐96‐5p to IGF2BP2 and TRIM52‐AS1 to IGF2BP2 were verified by dual‐luciferase or RNA pull‐down assays. These experiments revealed an up‐expression of miR‐96‐5p and IGF2BP2 while an under‐expression of TRIM52‐AS1 in CC cells. After DDP treatment, miR‐96‐5p inhibition increased apoptosis and decreased proliferation and DDP resistance. miR‐96‐5p bound to TRIM52‐AS1 and downregulated TRIM52‐AS1 expression, and TRIM52‐AS1 bound to IGF2BP2 to inhibit IGF2BP2 expression. TRIM52‐AS1 inhibition or IGF2BP2 overexpression neutralized the inhibition of silencing miR‐96‐5p on CC cell resistance to DDP. Overall, miR‐96‐5p improved CC cell resistance to DDP by inhibiting TRIM52‐AS1 and promoting IGF2BP2.

Keywords

• cervical cancer
• cisplatin
• IGF2BP2
• lncRNA TRIM52‐AS1